Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1600 1635 1637 1658 1674 4100
This examiner grants 71% of resolved cases
Jane J. Zara is an examiner in Art Unit 1600 of Tech Center 4100 with a portfolio of 1106 resolved cases. She maintains an allowance rate of 71.0 percent. This 71.0 percent rate suggests that a majority of cases are successfully prosecuted. The median days to allowance is 1061. This 1061-day figure is a duration for prosecution in this field. Practitioners should use this metric to manage client expectations regarding pendency in Art Unit 1600.
An interview lift of 16.1 percent indicates that engaging in a dialogue with the examiner can increase the chances of success. This 16.1 percent lift is a data point for strategy planning and suggests that interviews are a productive use of resources. With 1106 resolved cases, the allowance rate is a reliable indicator of the examiner's historical tendencies. The 16.1 percent lift remains a tool for overcoming specific rejections. The data from Tech Center 4100 indicates a consistent prosecution environment.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18396613 | BRANCHED OLIGONUCLEOTIDES | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 18535105 | Treatment Of Prion Diseases | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18061632 | TEMPLATE GUIDE RNA MOLECULES | Non-Final OA | FLAGSHIP PIONEERING INNOVATIONS VI, LLC |
| 17773682 | TARGETING NONSENSE-MEDIATED DECAY TO ACTIVATE P53 PATHWAY FOR THE TREATMENT OF CANCER | Non-Final OA | Board of Regents, The University of Texas System |
| 18283615 | COMPOSITIONS AND METHODS FOR TARGETED SYSTEMIC DELIVERY TO CELLS | Non-Final OA | The Board of Regents of the University of Texas System |
| 18234690 | RNA-TRIGGERED PROTEIN CLEAVAGE AND APPLICATIONS BY THE CRISPR CAS7-11-CSX29 COMPLEX | Final Rejection | The University of Tokyo |
| 18533784 | COMPOSITIONS AND METHODS FOR TREATING RIGHT VENTRICLE DYSFUNCTION | Non-Final OA | The United States Government As Represented By The Department Of Veterans Affairs |
| 18546795 | VIRAL DELIVERY OF A SIALIDASE TO TREAT CANCER | Non-Final OA | UNIVERSITÄT BASEL |
| 18389245 | SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 18392869 | CHIMERIC DOUBLE-STRANDED NUCLEIC ACID | Non-Final OA | Osaka University |
| 17758480 | COMPOSISTIONS AND METHODS FOR CRISPR ENABLED DNA SYNTHESIS | Non-Final OA | Duke University |
| 18286029 | IMPROVED COMPOSITIONS FOR DELIVERY OF MRNA | Non-Final OA | TRANSLATE BIO, INC. |
| 18488520 | ENZYMES WITH RUVC DOMAINS | Non-Final OA | Metagenomi Therapeutics, Inc. |
| 18565575 | GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING HYDROXYACID OXIDASE 1 (HAO1) AND USES THEREOF | Non-Final OA | Arbor Biotechnologies, Inc. |
| 18012769 | CONJUGATE OF GALNAC AND SAPONIN, THERAPEUTIC COMPOSITION COMPRISING SAID CONJUGATE AND A GALNAC-OLIGONUCLEOTIDE CONJUGATE | Non-Final OA | SAPREME TECHNOLOGIES B.V. |
| 17415759 | DRUG CONJUGATE | Final Rejection | Sapreme Technologies B.V. |
| 18056931 | Compositions of DNA Molecules, Methods of Making Therefor, and Methods of Use Thereof | Non-Final OA | NATIONAL RESILIENCE, LLC |
| 18465335 | SYSTEMS AND METHODS FOR PROTEIN EXPRESSION | Non-Final OA | ExcepGen Inc |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy